hES cells and/or their derivatives are used for the treatment of Eye Disorders, said treatment comprising administering 750,000 to 160 million hES cells and/or their derivatives, wherein said cells comprise neuronal stem cell progenitors, hematopoietic stem cell progenitors and/or mesenchymal stem cell progenitors, via local intravenous injection, subcutaneous injection intramuscular injection, retrobulbar injection, intravitreous injection or topical application, or combinations thereof.